MX2017008373A - Compuestos, composiciones y metodos. - Google Patents
Compuestos, composiciones y metodos.Info
- Publication number
- MX2017008373A MX2017008373A MX2017008373A MX2017008373A MX2017008373A MX 2017008373 A MX2017008373 A MX 2017008373A MX 2017008373 A MX2017008373 A MX 2017008373A MX 2017008373 A MX2017008373 A MX 2017008373A MX 2017008373 A MX2017008373 A MX 2017008373A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- methods
- polymorphic forms
- compounds
- micronized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El tema revelado suministra ciertas formas polimórficas del Compuesto (I) (ver Fórmula) así como también composiciones farmacéuticas que comprenden el Compuesto (I) o las formas polimórficas mencionadas, y métodos para la utilización y formulación de dichos Compuestos y composiciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096077P | 2014-12-23 | 2014-12-23 | |
PCT/US2015/066741 WO2016106135A1 (en) | 2014-12-23 | 2015-12-18 | Compounds, compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017008373A true MX2017008373A (es) | 2017-10-19 |
Family
ID=56151455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017008373A MX2017008373A (es) | 2014-12-23 | 2015-12-18 | Compuestos, composiciones y metodos. |
Country Status (14)
Country | Link |
---|---|
US (4) | US10202363B2 (es) |
EP (1) | EP3237399B1 (es) |
JP (1) | JP2018506514A (es) |
KR (1) | KR20170113553A (es) |
CN (1) | CN107108560B (es) |
AR (1) | AR103209A1 (es) |
AU (1) | AU2015369903B2 (es) |
BR (1) | BR112017013593A2 (es) |
CA (1) | CA2970958A1 (es) |
ES (1) | ES2939296T3 (es) |
MX (1) | MX2017008373A (es) |
RU (1) | RU2017126462A (es) |
TW (2) | TW201817725A (es) |
WO (1) | WO2016106135A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018506514A (ja) * | 2014-12-23 | 2018-03-08 | セレコー,インコーポレイテッド | 化合物、組成物および方法 |
US11464756B1 (en) | 2017-05-19 | 2022-10-11 | Jerry Darm | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof |
JP7158425B2 (ja) * | 2017-06-30 | 2022-10-21 | チェイス セラピューティクス コーポレイション | Nk-1アンタゴニスト組成物およびうつ病の処置における使用法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS567710A (en) | 1979-06-28 | 1981-01-27 | Sansho Seiyaku Kk | Whitening cosmetic |
ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
US6638534B1 (en) | 1998-07-28 | 2003-10-28 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
PL1648882T3 (pl) * | 2003-06-04 | 2008-12-31 | Merck & Co Inc | 3-Fluoro-piperydyny jako antagoniści NMDA/NR2B |
CA2591738A1 (en) * | 2004-12-22 | 2006-06-29 | Merck & Co., Inc. | Process for making substituted piperidines |
US20120289465A1 (en) * | 2009-11-25 | 2012-11-15 | Gcbio Corp. | Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
JP6042968B2 (ja) * | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
US20180271869A1 (en) * | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
JP2018506514A (ja) * | 2014-12-23 | 2018-03-08 | セレコー,インコーポレイテッド | 化合物、組成物および方法 |
-
2015
- 2015-12-18 JP JP2017534602A patent/JP2018506514A/ja active Pending
- 2015-12-18 KR KR1020177020421A patent/KR20170113553A/ko not_active Application Discontinuation
- 2015-12-18 AU AU2015369903A patent/AU2015369903B2/en active Active
- 2015-12-18 BR BR112017013593-0A patent/BR112017013593A2/pt not_active Application Discontinuation
- 2015-12-18 CA CA2970958A patent/CA2970958A1/en active Pending
- 2015-12-18 CN CN201580070348.0A patent/CN107108560B/zh active Active
- 2015-12-18 ES ES15874198T patent/ES2939296T3/es active Active
- 2015-12-18 RU RU2017126462A patent/RU2017126462A/ru not_active Application Discontinuation
- 2015-12-18 WO PCT/US2015/066741 patent/WO2016106135A1/en active Application Filing
- 2015-12-18 US US15/538,015 patent/US10202363B2/en active Active
- 2015-12-18 MX MX2017008373A patent/MX2017008373A/es unknown
- 2015-12-18 EP EP15874198.3A patent/EP3237399B1/en active Active
- 2015-12-21 AR ARP150104217A patent/AR103209A1/es unknown
- 2015-12-23 TW TW106128135A patent/TW201817725A/zh unknown
- 2015-12-23 TW TW104143455A patent/TW201630902A/zh unknown
-
2019
- 2019-02-11 US US16/272,788 patent/US10710976B2/en active Active
-
2020
- 2020-05-27 US US16/884,848 patent/US11479542B2/en active Active
-
2022
- 2022-09-23 US US17/934,772 patent/US20230257363A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3237399A1 (en) | 2017-11-01 |
EP3237399A4 (en) | 2018-08-15 |
US10710976B2 (en) | 2020-07-14 |
AU2015369903A1 (en) | 2017-07-27 |
RU2017126462A3 (es) | 2019-01-24 |
TW201817725A (zh) | 2018-05-16 |
CN107108560A (zh) | 2017-08-29 |
TW201630902A (zh) | 2016-09-01 |
CA2970958A1 (en) | 2016-06-30 |
AR103209A1 (es) | 2017-04-26 |
WO2016106135A1 (en) | 2016-06-30 |
AU2015369903B2 (en) | 2020-07-02 |
US20230257363A1 (en) | 2023-08-17 |
US20210107892A1 (en) | 2021-04-15 |
US10202363B2 (en) | 2019-02-12 |
JP2018506514A (ja) | 2018-03-08 |
EP3237399B1 (en) | 2022-11-30 |
KR20170113553A (ko) | 2017-10-12 |
US20190177299A1 (en) | 2019-06-13 |
RU2017126462A (ru) | 2019-01-24 |
BR112017013593A2 (pt) | 2018-06-19 |
US11479542B2 (en) | 2022-10-25 |
ES2939296T3 (es) | 2023-04-20 |
CN107108560B (zh) | 2020-11-10 |
US20170369469A1 (en) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014128A (es) | Polimorfos de selinexor. | |
MX2019002356A (es) | Compuestos de biarilo utiles como inmunomoduladores. | |
TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
MX2018003656A (es) | Formas cristalinas de mononucleotido de beta-nicotinamida. | |
WO2015101957A3 (en) | Inhibitors of glutaminase | |
MX362418B (es) | Composiciones aglutinantes para tabletas. | |
PH12016502050A1 (en) | Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation | |
WO2014131422A3 (en) | Fermented rapeseed feed ingredient | |
PH12019500822A1 (en) | Crystalline forms of eravacycline | |
NZ735736A (en) | Acetate salt of buprenorphine and methods for preparing buprenorphine | |
PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
IL249599B (en) | Compositions containing tempol, cholecalciferol, or derivatives or salts of same, for treating cerebral cavernous malformation (ccm) | |
MX2017008373A (es) | Compuestos, composiciones y metodos. | |
PH12016501393A1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
EP3403656A4 (en) | COMPOSITION FOR PREVENTING, HEALING OR TREATING THE FEMALE CLIMATE SYNDROME WITH LOGANINE OR DERIVATIVES THEREOF AS AN ACTIVE SUBSTANCE | |
MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
GB2530226A (en) | Chewable tablet | |
WO2017029642A3 (en) | Novel polymorphs of dolutegravir and salts thereof | |
GB2559718B (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
PH12015502703A1 (en) | Pharmaceutical compositions | |
MX2017004770A (es) | Formas solidas del clorhidrato de nilotinib. | |
NZ767083A (en) | Polymorphs of selinexor | |
WO2016027211A3 (en) | Process for the preparation of cinacalcet and its pharmaceutically acceptable salts |